Skip to main content

RETRACTION article

Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1561887

Retraction: A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice

Provisionally accepted
Frontiers Editorial Office Frontiers Editorial Office *
  • Frontiers Media SA, Lausanne, Switzerland

This article is a retraction of:

  1. A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice

    1. Read original article

The final, formatted version of the article will be published soon.

    Please find the retraction statement below:Mohammad S, Al Zoubi S, Collotta D, Krieg N, Wissuwa B, Alves G F, Purvis G S D, Norata G D, Baragetti A, Catapano A L, Solito E, Zechendorf E, Schürholz T, Correa-Vargas W, Brandenburg K, Coldewey S M, Collino M, Yaqoob M M, Martin L, Thiemermann C (2021) A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. Front. Immunol. 12:701275. doi: 10.3389/fimmu.2021.710275Following publication, concerns were raised regarding the integrity of the images in the published figures. Specifically, unexpected similarity was detected between western blot images presented in Figure 7. An investigation was conducted in accordance with Frontiers’ policies. The authors provided raw data for assessment, but the concerns could not be fully resolved. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted. This retraction was approved by the Chief Editors of Frontiers in Immunology and the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication is recorded by the publisher.

    Keywords: Peptide 19-2.5, high-fat diet, type-2 diabetes, Antimicrobial peptide, Insulin Resistance, steatohepatitis, microalbuminuria

    Received: 16 Jan 2025; Accepted: 16 Jan 2025.

    Copyright: © 2025 Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.